Page 19 - Educacional Ponenecias Congreso SEHH-STH 2020

5. Bonanad S, De la Rubia J, Gironella M, Pérez Persona E, González B, Fernán- dez Lago C, et al. Development and psychometric validation of a brief com- prehensive health status assessment scale in older patients with hemato- logical malignancies:The GAH Scale. J Geriatr Oncol. 2015;6:353-61.
6. Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275-91.
7. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424-47.
8. Megías-Vericat JE, Martínez-Cuadrón, D, Sanz MA, Montesinos P. Salvage regi- mens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. Ann Hematol. 2018;97:1115-53.
9. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377:454-64.
10. Castaigne S, Pautas C,Terré C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379:1508-16.
11. Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Denis Caillot D, et al. Gem- tuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III. ALFA-0701 trial. Haematologi- ca. 2019;104:113-9.
12. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cyta- rabine and daunorubicin) Liposome for Injection Versus Conventional Cyta-
rabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary
Acute Myeloid Leukemia. J Clin Oncol. 2018;36:2684-92.
13. DiNardo CD,Jonas BA,Pullarkat V,Thirman MJ,García JS,Wei AH,et al.Azacit- idine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl
J Med. 2020;383:617-29.
14. Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, et al. Random-
ized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33:379-89.
15. DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Du- rable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018;378:2386-98.
16. Eytan M, Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, et al. Ena- sidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722-31.
17. Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteri- tinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019;381:1728-40.
18. Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, et al. The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral For- mulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission. Blood. 2019;134(Supplement_2):LBA-3.
19. Liu Y, Bewersdorf JP, Stahl M, Zeidan AM. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? Blood Rev. 2019;34:67-83.
LXII Congreso Nacional SEHH-XXXVI Congreso Nacional SETH / Programa Educacional
19